News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
765,122 Results
Type
Article (59384)
Company Profile (343)
Press Release (705395)
Section
Business (217756)
Career Advice (2613)
Deals (37667)
Drug Delivery (122)
Drug Development (86252)
Employer Resources (179)
FDA (17436)
Job Trends (16188)
News (369834)
Policy (36021)
Tag
2024 BioCapital Digital (13)
2024 BioForest Digital (6)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (19)
2024 Biotech Beach Digital (11)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (7)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2927)
Accelerated approval (5)
Adcomms (27)
Allergies (87)
Alliances (53476)
ALS (93)
Alzheimer's disease (1452)
Antibody-drug conjugate (ADC) (130)
Approvals (17417)
Artificial intelligence (266)
Autoimmune disease (22)
Automation (14)
Bankruptcy (381)
Best Places to Work (12375)
BIOSECURE Act (19)
Biosimilars (109)
Biotechnology (233)
Bladder cancer (64)
Brain cancer (29)
Breast cancer (268)
Cancer (2139)
Cardiovascular disease (181)
Career advice (2183)
Career pathing (32)
CAR-T (153)
Cell therapy (426)
Cervical cancer (21)
Clinical research (69565)
Collaboration (828)
Compensation (473)
Complete response letters (27)
COVID-19 (2818)
CRISPR (41)
C-suite (225)
Cystic fibrosis (105)
Data (2021)
Decentralized trials (2)
Denatured (28)
Depression (49)
Diabetes (267)
Diagnostics (6728)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (46)
Drug discovery (119)
Drug pricing (116)
Drug shortages (31)
Duchenne muscular dystrophy (90)
Earnings (89621)
Editorial (38)
Employer branding (22)
Employer resources (154)
Events (120200)
Executive appointments (678)
FDA (18612)
Featured Employer (56)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (740)
Gene editing (107)
Generative AI (26)
Gene therapy (310)
GLP-1 (784)
Government (4851)
Grass and pollen (5)
Guidances (49)
Healthcare (20481)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (121)
Indications (27)
Infectious disease (2962)
Inflammatory bowel disease (146)
Inflation Reduction Act (9)
Influenza (51)
Intellectual property (88)
Interviews (441)
IPO (17330)
IRA (45)
Job creations (4257)
Job search strategy (1854)
Kidney cancer (10)
Labor market (34)
Layoffs (506)
Leadership (19)
Legal (8833)
Liver cancer (75)
Lung cancer (314)
Lymphoma (138)
Machine learning (4)
Management (61)
Manufacturing (293)
MASH (66)
Medical device (14477)
Medtech (14482)
Mergers & acquisitions (20817)
Metabolic disorders (703)
Multiple sclerosis (77)
NASH (21)
Neurodegenerative disease (99)
Neuropsychiatric disorders (30)
Neuroscience (1982)
NextGen: Class of 2025 (7264)
Non-profit (4949)
Northern California (2478)
Now hiring (37)
Obesity (383)
Opinion (257)
Ovarian cancer (75)
Pain (88)
Pancreatic cancer (79)
Parkinson's disease (143)
Partnered (20)
Patents (214)
Patient recruitment (99)
Peanut (51)
People (61377)
Pharmaceutical (85)
Pharmacy benefit managers (21)
Phase I (21583)
Phase II (30516)
Phase III (22879)
Pipeline (1086)
Podcasts (78)
Policy (126)
Postmarket research (2924)
Preclinical (9319)
Press Release (71)
Prostate cancer (99)
Psychedelics (34)
Radiopharmaceuticals (268)
Rare diseases (398)
Real estate (6573)
Recruiting (68)
Regulatory (24447)
Reports (48)
Research institute (2596)
Resumes & cover letters (421)
Rett syndrome (4)
RNA editing (4)
RSV (45)
Schizophrenia (73)
Series A (131)
Series B (84)
Service/supplier (14)
Sickle cell disease (53)
Southern California (2161)
Special edition (18)
Spinal muscular atrophy (161)
Sponsored (31)
Startups (4086)
State (2)
Stomach cancer (16)
Supply chain (63)
The Weekly (48)
United States (22145)
Vaccines (756)
Venture capitalists (38)
Webinars (12)
Weight loss (275)
Women's health (36)
Worklife (18)
Date
Today (127)
Last 7 days (711)
Last 30 days (2858)
Last 365 days (35246)
2025 (8598)
2024 (36974)
2023 (41965)
2022 (53281)
2021 (58053)
2020 (56921)
2019 (50273)
2018 (38181)
2017 (35171)
2016 (35387)
2015 (41307)
2014 (35133)
2013 (30601)
2012 (32786)
2011 (33408)
2010 (32057)
Location
Africa (928)
Alabama (50)
Alaska (7)
Arizona (242)
Arkansas (14)
Asia (43435)
Australia (7299)
California (5700)
Canada (1899)
China (501)
Colorado (260)
Connecticut (276)
Delaware (134)
Europe (96202)
Florida (836)
Georgia (206)
Idaho (62)
Illinois (554)
India (26)
Indiana (303)
Iowa (9)
Japan (145)
Kansas (104)
Kentucky (24)
Louisiana (8)
Maine (61)
Maryland (888)
Massachusetts (4380)
Michigan (217)
Minnesota (388)
Mississippi (2)
Missouri (85)
Montana (31)
Nebraska (25)
Nevada (58)
New Hampshire (68)
New Jersey (1648)
New Mexico (30)
New York (1646)
North Carolina (1009)
North Dakota (8)
Northern California (2478)
Ohio (198)
Oklahoma (15)
Oregon (38)
Pennsylvania (1283)
Puerto Rico (10)
Rhode Island (28)
South America (1319)
South Carolina (19)
South Dakota (1)
Southern California (2161)
Tennessee (96)
Texas (854)
Utah (170)
Virginia (141)
Washington D.C. (62)
Washington State (539)
West Virginia (3)
Wisconsin (52)
765,122 Results for "ra medical systems inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
March 25, 2025
·
11 min read
Press Releases
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
April 3, 2025
·
5 min read
Press Releases
Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025
April 1, 2025
·
1 min read
Press Releases
Inspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Healthcare Forum
March 6, 2025
·
1 min read
Drug Development
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.
May 16, 2024
·
10 min read
Press Releases
SetPoint Medical Announces Late-Breaking Data from RESET-RA Study at ACR Convergence 2024
November 18, 2024
·
5 min read
Business
Ra Medical Systems Announces First Quarter 2023 Results
Ra Medical Systems, Inc. announced financial and company highlights for the first quarter ended March 31,2023.
June 2, 2023
·
12 min read
Press Releases
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
January 23, 2025
·
13 min read
Drug Development
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of two peer-reviewed research papers in Nature.
April 8, 2024
·
8 min read
Press Releases
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
February 12, 2025
·
13 min read
1 of 76,513
Next
